

Sharma V, Wakode SR, Lather V, Mathur R, Fernandes MX. Structure based rational drug design of selective phosphodiesterase-4 ligands as anti-inflammatory molecules. *Bull. Pharm. Res.* 2011; 1(2):33-40.

References (12):

1. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. *Proc. Natl. Acad. Sci. U S A.* 2002;99(11):7628-33.
<http://www.pnas.org/content/99/11/7628.full.pdf>
2. Macdonald D, Perrier H, Liu S, Laliberte F, Rasori R, Robichaud A, Masson P, Huang Z. Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6-[(4-iodo-1H-1-imidazolyl) methyl] quinoline (APIIMQ). *J. Med. Chem.* 2000;43(21):3820-3.
http://www.merckfrosst.ca/assets/en/pdf/research/medicinal_chem/publications/2000/J.Med.Chem.43p3820.pdf
3. Burnouf C, Pruniaux M-P, Szilagyi CM. Chapter 10. Phosphodiesterases 4 inhibitors. *Ann. Rep. Med. Chem.* 1998;33:91-109.
<http://www.sciencedirect.com/science/article/pii/S0065774308610751>
4. Kranz M, Wall M, Evans B, Miah A, Ballantine S, Delves C, Dombroski B, Gross J, Schneck J, Villa JP, Neu M, Somers DO. Identification of PDE4B over 4D subtype-selective inhibitors revealing an unprecedented binding mode. *Bioorg. Med. Chem.* 2009;17(14):5336-41.
<http://www.sciencedirect.com/science/article/pii/S0968089609003228>
5. Librowski T, Czarnecki R, Czekaj T, Marona H. New xanthone derivatives as potent anti-inflammatory agents. *Medicina (Kaunas)* 2005;41(1):54-8.
<http://medicina.kmu.lt/0501/0501-08e.pdf>
6. Chung M-I, Weng J-R, Wang J-P, Teng C-M, Lin C-N. Antiplatelet and anti-inflammatory constituents and new oxygenated xanthenes from *Hypericum geminiflorum*. *Planta Med.* 2002;68(1):25-9.
<https://www.thieme-connect.com/ejournals/abstract/plantamedica/doi/10.1055/s-2002-19871>
7. Lin C-N, Chung M-I, Liou S-J, Lee T-H, Wang J-P. Synthesis and anti-inflammatory effects of xanthone derivatives. *J. Pharm. Pharmacol.* 1996;48(5):532-8.
<http://onlinelibrary.wiley.com/doi/10.1111/j.2042-7158.1996.tb05969.x/abstract>
8. Marona H. Evaluation of some 2-substituted derivatives of xanthone for anticonvulsant properties. *Pharmazie* 1998;53(6):405-9.
<http://www.ncbi.nlm.nih.gov/pubmed/9675771>
9. Shankaranarayan D, Gopalakrishnan C, Kameswaran L. Pharmacological profile of mangostin and its derivatives. *Arch. Int. Pharmacodyn. Ther.* 1979;239(2):257-69.
<http://www.ncbi.nlm.nih.gov/pubmed/314790>

10. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *J. Med. Chem.* 2004;47(7):1739-49.
<http://pubs.acs.org/doi/abs/10.1021/jm0306430>
11. Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B, Luu C, Tabrizizad M, Gillette S, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim S-H, Schlessinger J, Zhang KYJ. Structural basis for the activity of drugs that inhibit phosphodiesterases. *Structure* 2004;12(12):2233-47. <http://download.cell.com/structure/pdf/PIIS0969212604003727.pdf>
12. Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. *Neuropharmacology* 2001;40(2):262-9.
<http://www.ncbi.nlm.nih.gov/pubmed/11114405>

